Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your body to burn more fat instead and hang on to muscle. There’s also a beneficial metabolic effect: muscle tissue burns more calories at rest than fat, which can support long-term weight management.

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) and Novo Nordisk A/S (NVO) seeing stock prices soar. These medications are reshaping a health care market that serves the 40% of U.

Australia's agriculture sector is poised for a strong year, but the Trump presidency, global conflicts and anti-obesity medications are creating uncertainty.